• BioElectronicsis (Frederick, Maryland), a developer of drug-free, anti-inflammatory patches, said that it is entering into an agreement with DataMedix (Newtown Square, Pennsylvania), a full service clinical research support organization. DataMedix will coordinate the launch of a clinical trials program for the company’s lead product, ActiPatch, in the areas of orthopedics, podiatry, chiropractics, rehabilitation, post-surgical and wound care. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a few dollars a day.

• Boston Scientific (Natick, Massachusetts) reported the U.S. launch of its Matrix2 360-degree Detachable Coils, which have been cleared by the FDA for the treatment of brain aneurysms. The Matrix2 360-degree Detachable Coils feature a new 360-degree complex shape designed to allow greater conformability and more uniform distribution within intracranial aneurysms. The design includes 1.5 loops at the beginning of the coil that are 25% smaller than the overall coil diameter. This multi-diameter design is intended to offer more precise, controlled delivery and facilitate first-time placement. The smooth biopolymer coil surface also decreases coil-on-coil friction by 35% over the company’s first generation coils in order to facilitate coil delivery and promote aneurysm packing. The Matrix2 coils leverage established GDC 10 technology, which has already been used to treat more than 10,000 patients worldwide. The product line now offers coil diameter sizes ranging from 2 mm to 24 mm and coil lengths from 4 mm to 40 mm.

No Comments